Literature DB >> 2866061

Sulphasalazine and derivatives, natural killer activity and ulcerative colitis.

P R Gibson, D P Jewell.   

Abstract

The effects of sulphasalazine, 5-aminosalicylic acid (5-ASA), sulphapyridine and azodisalicylic acid (ADS) in vitro on the natural killer (NK) activity of peripheral blood mononuclear cells (MNC) have been examined and compared with those of the lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA) and the cyclooxygenase inhibitor, indomethacin. Sulphasalazine, sulphapyridine and ADS inhibited NK activity with 50% inhibitory concentrations (IC50) of 0.7, 2.5 and 4.0 mmol/l respectively. The effect was rapidly reversible. In contrast, 5-ASA minimally inhibited NK activity at 50 mmol/l only. NDGA potently inhibited NK activity (IC50 27 mumol/l) but this was only partly reversible in short term incubations. Indomethacin had no effect at concentrations less than those inhibiting cyclo-oxygenase activity (1-10 mumol/l) but potently and reversibly inhibited NK activity at or above 25 mumol/l. The inhibitory effects observed were unlikely to be due to direct toxicity of effector cells as 5-ASA, sulphapyridine and ADS had no effect on the viability of peripheral blood MNC, whereas NDGA and indomethacin lysed MNC only at maximal concentrations tested. Though sulphasalazine produced MNC lysis at and above 1 mmol/l, the rapid reversibility of the inhibition of NK activity at 1 mmol/l suggested that lysis of NK cells contributed little to the suppressive effect at this concentration. The disparity of the therapeutic efficacy and effects on NK activity of sulphasalazine and its derivatives in vitro may suggest that NK activity is not a major pathogenic mechanism in ulcerative colitis. Any inhibitory effect on cellular immune function of indomethacin does not necessarily reflect an effect of cyclo-oxygenase inhibition.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866061     DOI: 10.1042/cs0690177

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  12 in total

Review 1.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

Review 2.  Sulphasalazine in ulcerative colitis: in memoriam?

Authors:  J Hayllar; I Bjarnason
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

3.  Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.

Authors:  M N Aparicio-Pagés; H W Verspaget; J C Hafkenscheid; G E Crama-Bohbouth; A S Peña; I T Weterman; H W Lamers
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

Review 4.  Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.

Authors:  A B Hawthorne; C J Hawkey
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

5.  Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid.

Authors:  M J Elder; J Leonard; J K Dart
Journal:  Br J Ophthalmol       Date:  1996-06       Impact factor: 4.638

6.  Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.

Authors:  G Frieri; R Giacomelli; M Pimpo; G Palumbo; A Passacantando; G Pantaleoni; R Caprilli
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

Review 7.  Inflammatory bowel disease.

Authors:  G M Van Rosendaal
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

8.  Interleukin 2 and interferon-gamma augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis.

Authors:  T Hibi; M Ohara; M Watanabe; T Kanai; H Takaishi; A Hayashi; Y Hosoda; H Ogata; Y Iwao; S Aiso
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

9.  Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine.

Authors:  E el-Omar; I Penman; G Cruikshank; S Dover; S Banerjee; C Williams; K E McColl
Journal:  Gut       Date:  1994-10       Impact factor: 23.059

Review 10.  Pharmacological and biochemical actions of sulphasalazine.

Authors:  J R Hoult
Journal:  Drugs       Date:  1986       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.